Senores Pharmaceuticals Limited has informed the Exchange regarding submission of Annual Secretarial Compliance Report for financial year ended March 31, 2026
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals Limited has submitted its Annual Secretarial Compliance Report for FY 2025-26, as required under SEBI Regulation 24A. The report was certified by Mukesh H. Shah & Co., a peer-reviewed practicing company secretary. The certification confirms that the company has generally complied with all applicable SEBI regulations including LODR, ICDR, SAST, PIT, and Depositories Regulations. The report indicates no deviations, no actions taken by SEBI or stock exchanges against the company, its promoters, or directors, and no observations from the previous year. All secretarial standards were met, related party transactions had prior audit committee approval, and the company maintains proper documentation and website disclosures.
This is a routine compliance filing with positive implications for shareholders. A clean secretarial compliance report with no observations or penalties indicates good corporate governance and regulatory adherence, which is reassuring for investors concerned about governance standards.